Otrivin rhinitis Plus metered spray Fl 10 ml
Otrivin Schnupfen Plus Dosierspray Fl 10 ml
-
22.84 CHF
You save 0 / 0%
Buy 2 and save 9.00 CHF / -22%
- Availability: In stock
- Distributor: GSK CONS. HEALTHC. AG
- Product Code: 7667411
- ATC-code R01AB06
- EAN 7680669920012
Ingredients:
Bestsellers
Description
What is Otrivin Cold Plus and when is it used?
Otrivin Cold Plus is a dosing spray with a spray device and contains two active ingredients: Xylometazoline has vasoconstrictive properties and thereby reduces the swelling of the mucous membranes. Dexpanthenol is a derivative of the vitamin pantothenic acid, which is characterized by its properties that promote wound healing and protect the mucous membrane.
Otrivin Cold Plus is used to reduce swelling of the nasal mucosa in the event of a cold. With a doctor's prescription, Otrivin Cold Plus can also be used to treat attacks of runny nose (rhinitis vasomotorica) and to treat obstructed nasal breathing after nasal surgery.
Otrivin Cold Plus is intended for adults and adolescents aged 12 and over .
When must Otrivin Schnupfen Plus not be used?
This medicine must not be used in the case of:
- Hypersensitivity to the active ingredients xylometazoline hydrochloride, dexpanthenol or one of the excipients,
- very dry or chronically inflamed nasal mucosa (rhinitis sicca or atrophic rhinitis),
- narrow-angle glaucoma (glaucoma, increased intraocular pressure), li>
- After transnasal surgery (surgical intervention in the nose area) in which the meninges were exposed.
- Children under the age of 12.
When is the Do you have to be careful when using Otrivin Schnupfen Plus?
With longer use or higher dosages of Otrivin Schnupfen Plus, effects on the heart and circulatory system or the nervous system cannot be ruled out. In these cases, the ability to drive and use machines may be impaired.
In the following cases, Otrivin Schnupfen Plus should be used with caution and only after consultation with your doctor or pharmacist be:
- if you are being treated with monoamine oxidase inhibitors (MAOIs) and other potentially blood pressure-increasing medicines,
- if you have high blood pressure, heart and circulatory diseases (e.g. long-QT syndrome). Patients suffering from long QT syndrome may experience severe cardiac arrhythmias when using Otrivin Schnupfen Plus.
- Pheochromocytoma (a type of cancer),
- Overactive thyroid (hyperthyroidism ),
- Sugar disease (diabetes),
- Enlarged prostate.
Continuous treatment with Otrivin Cold Plus lasting longer than 1 week does not require a doctor instruction not shown. Long-term use of Otrivin Schnupfen Plus can lead to chronic swelling (which is very similar to a cold) and ultimately to atrophy of the nasal mucosa.
The recommended dosage must not be exceeded, especially in young people and elderly patients.
Otrivin Schnupfen Plus contains the preservative benzalkonium chloride, which can cause irritation of the nasal mucosa.Inform your doctor, pharmacist or druggist if you
- suffer from other diseases,
- have allergies or
- use other medicines (including those you bought yourself!)! ul>
- Do not cut off the spray attachment.
- Clean your nose (blow your nose) before use.
- Remove the protective cap.
- Hold the bottle upright with your thumb on the bottom and the spray head between two fingers.
- Bend your head slightly forward and insert the spray head into one nostril.
- Spray once and at the same time breathe in gently through your nose.
- Repeat the application in the other nostril.
- Wipe the spray head after use and put the protective cap back on immediately.
- difficulty breathing and swallowing,
- swelling of the face, lips, tongue and/or in the neck area,
- severe itching with a red rash and/or elevations on the skin.
May Otrivin Schnupfen Plus be used during pregnancy or while breastfeeding?
Otrivin Schnupfen Plus should not be used during pregnancy as there are insufficient studies on the unborn child.
It should not be used while breastfeeding, as it is not known whether the active ingredient xylometazoline hydrochloride passes into breast milk.
How do you use Otrivin Schnupfen Plus?
Sniffles:
Unless otherwise prescribed, adults and adolescents aged 12 and over inject one spray of Otrivin Colds Plus into each nostril up to 3 times a day as needed. Breathe in gently through your nose while spraying. The frequency of use depends on the individual sensitivity and the clinical effect.
After surgical interventions on the nose: according to the doctor's prescription.
Application instructions for the dosing spray (without propellant)
Before the first application, press the pump 3 times until an even spray mist emerges into the air. For further applications, the dosing spray is immediately ready for use. If the spray does not come out completely, e.g. after an interruption in use, the pump must be operated about twice again.
Ensure that the spray does not come into contact with the eyes.
The dosing spray should only be used by one person to avoid any spread to avoid infection.
Otrivin Schnupfen Plus should not be used for longer than 7 days unless directed by a doctor.
Re-application should only take place after a break of several days .
The doctor should always be asked about the duration of use in young people.
The recommended dosage must not be exceeded, especially in young people and older patients.
The last application of the day should preferably be shortly before going to bed.
If you forget to use Otrivin Schnupfen Plus, do not use twice the amount next time, but follow the application as described in the dosing instructions Continue as described.
Observe the dosage given in the package leaflet or prescribed by your doctor. If you think the medicine is too weak or too strong, talk to your doctor, pharmacist or druggist.
What side effects can Otrivin Schnupfen Plus have?
Stop using Otrivin Schnupfen Plus and seek medical help immediately if you experience any of the following symptoms; it could be an allergic reaction:The following side effects can occur when using Otrivin Schnupfen Plus:
Respiratory system
Otrivin Schnupfen Plus can cause temporary mild irritation (burning or dryness of the nasal mucosa), particularly in sensitive patients.
After the effect has worn off, there is often increased swelling of the mucous membrane ( reactive hyperaemia).
Prolonged or frequent use as well as a higher dosage of Otrivin Schnupfen Plus can lead to symptoms of irritation (burning or dryness of the mucous membrane) and increased swelling of the mucous membranes, which are aggravated by increased use of medicines (rhinitis medicamentosa). This effect can already occur after 5 days of treatments and cause permanent damage to the mucous membranes with crust formation (rhinitis sicca, stinky nose) with continued use.
Nervous system
Headaches, insomnia or fatigue occur rarely.
Heart and circulatory system
Occasionally, there are effects on the heart and circulatory system, such as palpitations, increased pulse rate, rise in blood pressure.
Immune system
In very rare cases, allergic reactions occur with shortness of breath.
If you notice any side effects that are not described here, you should inform your doctor, pharmacist or druggist.
What is also to be observed?
The medicinal product may only be used up to the date marked «EXP» on the container.
Storage instructions
At room temperature (15-25 °C).
Keep out of the reach of children.
Your doctor, pharmacist or druggist can provide you with further information. These people have the detailed technical information.
What does Otrivin Schnupfen Plus contain?
Active ingredients
1 ml solution contains: 1 mg xylometazoline hydrochloride and 50 mg dexpanthenol .
1 spray of 0.1 ml solution (corresponds to 0.10 g) contains 0.1 mg xylometazoline hydrochloride and 5.0 mg dexpanthenol.
Excipients
Disodium phosphate, potassium dihydrogen phosphate, preserved: benzalkonium chloride, water.
Authorization number
66992 (Swissmedic).
Where can you get Otrivin Schnupfen Plus? Which packs are available?
In pharmacies and drugstores, without a doctor's prescription.
Dosing spray of 10 ml.
Authorization holder
GSK Consumer Healthcare Schweiz AG, Risch.
This leaflet was last checked by the drug authority (Swissmedic) in November 2019.